Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sandra Horning | M | 75 | 4 years | |
| Jacqueline Barton | M | 71 | 6 years | |
| Muzammil Mansuri | M | 70 |
OrsoBio Inc
 OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation. | 7 years |
| Harish M. Manwani | M | 70 | 6 years | |
| Daniel O'Day | M | 59 | 5 years | |
| Andrew Dickinson | M | 54 | 8 years | |
| Kelly Kramer | F | 56 | 8 years | |
| Steven W. Pipe | M | - |
University of Michigan
| 31 years |
| Gans Ganapati | M | - |
OrsoBio Inc
OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation. | - |
| Joydeep Ganguly | M | - | 5 years | |
| Jyoti Mehra | F | 48 | 7 years | |
| Johanna Mercier | F | 54 | 5 years | |
| Srini Akkaraju Akkaraju | M | 56 |
OrsoBio Inc
OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation. | - |
| Alec Gallimore | M | 60 |
University of Michigan
| 32 years |
| Cory Freedland | M | 48 |
OrsoBio Inc
OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation. | - |
| Merdad Parsey | M | 61 | 5 years | |
| Bruce R. Maxim | M | 70 |
University of Michigan
| 33 years |
| Lennard A. Fisk | M | 80 |
University of Michigan
| 31 years |
| Robert Cook | M | 65 | 12 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregg Alton | M | 58 | 20 years | |
| John Milligan | M | 63 | 28 years | |
| Usama Mohammad Fayyad | M | 60 |
University of Michigan
| 11 years |
| Avi Rubin | M | - |
University of Michigan
| 9 years |
| H. Watkins | M | 71 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 8 years |
| Peter Barrett | M | 71 |
Celera Corp.
 Celera Corp. Medical/Nursing ServicesHealth Services Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA. | 4 years |
| Curran Simpson | M | 62 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 9 years |
| William A. Haseltine | M | 79 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 years |
| John McHutchison | M | 66 | 9 years | |
| Craig Zehnder | M | - |
University of Michigan
| - |
| Steven M. Katz | M | - |
University of Michigan
| 6 years |
| Lawrence Sage | M | - |
University of Michigan
| 7 years |
| Gordon Earle Moore | M | 95 | 17 years | |
| Marc L. Walinsky | M | - |
University of Michigan
| 5 years |
| Mark Alhermizi | M | - |
University of Michigan
| 7 years |
| John Eric Krakowiak | M | - |
University of Michigan
| 2 years |
| Daniel Moon | M | - |
University of Michigan
| 10 years |
| Andrew Cheng | M | 57 | 19 years | |
| Jason Park | M | 47 |
University of Michigan
| 5 years |
| Randy Winograd | M | - |
University of Michigan
| 7 years |
| Kevin P. McRaith | M | - |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | - |
| Daniel Beltzman | M | 49 |
University of Michigan
| 5 years |
| Dong-Yeon Kim | M | - |
University of Michigan
| 3 years |
| Jason L. Hertzberg | M | - |
University of Michigan
| 5 years |
| Paul Brown | M | - |
University of Michigan
| 16 years |
| Tonya Bakritzes | F | - |
University of Michigan
| 5 years |
| Andreas Utomo | M | 55 |
University of Michigan
| 5 years |
| Monica Tellado | F | 51 | 9 years | |
| David Dornan | M | 46 | 5 years | |
| Kok Siong Yun | M | 54 |
University of Michigan
| 5 years |
| Gísli S. Óttarsson | M | - |
University of Michigan
| 6 years |
| Tanju Carnation | M | - |
University of Michigan
| 7 years |
| Brian Scott Stutland | M | 49 |
University of Michigan
| 6 years |
| Jeneanne Hanley | F | 51 |
University of Michigan
| 10 years |
| Lisa McLaughlin | F | - |
University of Michigan
| 14 years |
| Kuan Hsu | M | - |
University of Michigan
| 6 years |
| Lori Wheeler-Naess | F | 53 |
University of Michigan
| 5 years |
| Michelle Epstein Taigman | F | 55 |
University of Michigan
| 7 years |
| D. Nordlund | M | - |
University of Michigan
| 3 years |
| David M. Kortenkamp | M | - |
University of Michigan
| 4 years |
| Tatiana Bailey | F | - |
University of Michigan
| 6 years |
| Stephen Antczak | M | - |
University of Michigan
| 5 years |
| Marc Weiser | M | - |
University of Michigan
| 9 years |
| Norbert W. Bischofberger | M | 68 | 28 years | |
| Charles Park | M | 57 |
University of Michigan
| 7 years |
| Paul A. Berg | M | 97 | 13 years | |
| John Madigan | M | 86 | 12 years | |
| David Southwell | M | 63 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 4 years |
| Tuan Ha-Ngoc | M | 72 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | - |
| Kevin B. Young | M | 66 | 10 years | |
| Kelli Turner | F | 53 |
University of Michigan
| 8 years |
| Michael S. Russell | M | - |
University of Michigan
| 7 years |
| Barry A. Labinger | M | 60 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 7 years |
| Mike K. Jung | M | 54 |
University of Michigan
| 3 years |
| Brian Stephen Matuszak | M | - |
University of Michigan
| 6 years |
| Robin Washington | F | 60 | 11 years | |
| James M. Denny | M | 91 | 17 years | |
| Adil Haque | M | - |
University of Michigan
| 4 years |
| Maxine Gowen | M | 66 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 4 years |
| Takaaki Wakasugi | M | 81 |
University of Michigan
| - |
| Gilles Gallant | M | - |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | - |
| Thomas J. Lewand | M | - |
University of Michigan
| 7 years |
| Dana L. Schmitt | F | - |
University of Michigan
| 6 years |
| Jason B. Koenig | M | - |
University of Michigan
| 7 years |
| Paul McCreadie | M | - |
University of Michigan
| 12 years |
| Ronald J. Lieberman | M | 54 |
University of Michigan
| 7 years |
| Douglass M. Rayburn | M | - |
University of Michigan
| 3 years |
| Augustine Lawlor | M | 67 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 8 years |
| David E. Wells | M | - |
University of Michigan
| 3 years |
| Robert C. Young | M | 84 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 7 years |
| John Martin | M | 72 | 29 years | |
| Morton Lorge | M | - |
University of Michigan
| 3 years |
| Barbara Weber | M | 67 |
University of Michigan
| 6 years |
| Chi Ho Lo | M | 51 |
University of Michigan
| 4 years |
| Adam Philip Graf | M | - |
University of Michigan
| 4 years |
| Michael Joseph Kelley | M | - |
University of Michigan
| 4 years |
| Matt HoganBruen | M | - |
University of Michigan
| 4 years |
| Snehal Amin | M | - |
University of Michigan
| 3 years |
| Boaz Weinstein | M | 51 |
University of Michigan
| 4 years |
| Adam J. Gacek | M | - |
University of Michigan
| 4 years |
| Gregory Robin | M | - |
University of Michigan
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| India | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mani Subramanian
- Personal Network
